Myriad Genetics Q1 EPS Forecast Decreased by Leerink Partnrs

Myriad Genetics, Inc. (NASDAQ:MYGN) – Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.18) per share for the quarter, down from their previous estimate of ($0.08). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.16) EPS.

Several other research analysts have also recently commented on MYGN. The Goldman Sachs Group lowered their target price on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $30.00 to $21.00 in a report on Monday, December 9th. Craig Hallum initiated coverage on shares of Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price objective on the stock. Piper Sandler lowered their target price on shares of Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $22.14.

Myriad Genetics Price Performance

Myriad Genetics stock opened at $10.73 on Friday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 52-week low of $9.76 and a 52-week high of $29.30. The firm has a market cap of $976.81 million, a PE ratio of -8.25 and a beta of 1.88. The company’s 50 day moving average is $13.28 and its two-hundred day moving average is $19.04.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The business had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the prior year, the company posted ($0.12) EPS.

Institutional Investors Weigh In On Myriad Genetics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nordea Investment Management AB increased its position in Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company’s stock valued at $4,548,000 after acquiring an additional 179,527 shares during the period. Jennison Associates LLC grew its stake in shares of Myriad Genetics by 144.2% in the 4th quarter. Jennison Associates LLC now owns 59,015 shares of the company’s stock valued at $809,000 after purchasing an additional 34,853 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of Myriad Genetics in the third quarter valued at approximately $1,965,000. Barclays PLC raised its stake in shares of Myriad Genetics by 136.9% during the third quarter. Barclays PLC now owns 190,243 shares of the company’s stock worth $5,210,000 after purchasing an additional 109,931 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Myriad Genetics during the third quarter worth $4,756,000. 99.02% of the stock is owned by hedge funds and other institutional investors.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.